Veru Inc. (NASDAQ:VERU – Free Report) – Equities researchers at B. Riley issued their Q1 2025 EPS estimates for Veru in a research note issued to investors on Thursday, January 9th. B. Riley analyst W. Wood forecasts that the company will earn ($0.08) per share for the quarter. The consensus estimate for Veru’s current full-year earnings is ($0.30) per share. B. Riley also issued estimates for Veru’s Q2 2025 earnings at ($0.05) EPS.
Veru (NASDAQ:VERU – Get Free Report) last issued its quarterly earnings data on Monday, December 16th. The company reported ($0.06) EPS for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.01. Veru had a negative return on equity of 115.99% and a negative net margin of 376.38%.
Check Out Our Latest Research Report on Veru
Veru Trading Down 2.5 %
Shares of VERU stock opened at $0.74 on Monday. Veru has a 1 year low of $0.36 and a 1 year high of $1.92. The firm has a market capitalization of $108.84 million, a P/E ratio of -1.55 and a beta of -0.53. The firm’s fifty day simple moving average is $0.69 and its 200 day simple moving average is $0.80.
Institutional Trading of Veru
Hedge funds have recently modified their holdings of the company. Zacks Investment Management acquired a new position in shares of Veru in the 3rd quarter valued at $25,000. Gladstone Institutional Advisory LLC grew its position in shares of Veru by 34.2% in the 3rd quarter. Gladstone Institutional Advisory LLC now owns 56,876 shares of the company’s stock valued at $44,000 after purchasing an additional 14,500 shares during the period. Weaver Consulting Group increased its stake in Veru by 41.0% during the 4th quarter. Weaver Consulting Group now owns 69,705 shares of the company’s stock worth $45,000 after purchasing an additional 20,280 shares in the last quarter. SG Americas Securities LLC raised its holdings in Veru by 185.9% during the 3rd quarter. SG Americas Securities LLC now owns 66,128 shares of the company’s stock worth $51,000 after buying an additional 42,997 shares during the period. Finally, Jane Street Group LLC lifted its stake in Veru by 142.8% in the third quarter. Jane Street Group LLC now owns 96,454 shares of the company’s stock valued at $74,000 after buying an additional 56,736 shares in the last quarter. 47.16% of the stock is currently owned by institutional investors and hedge funds.
About Veru
Veru Inc, a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections.
Further Reading
- Five stocks we like better than Veru
- How to Effectively Use the MarketBeat Ratings Screener
- The Fed Is More Likely to Hike Than Cut Rates in 2025
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- Investors Navigate Uncertainty by Seeking Refuge in Gold and Oil
- What Are the FAANG Stocks and Are They Good Investments?
- Archer Aviation Shares Slide, Now Bargain Priced for 2025
Receive News & Ratings for Veru Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veru and related companies with MarketBeat.com's FREE daily email newsletter.